Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+Non-small Cell Lung Cancer Das, M., Ogale, S., Johnson, A., Nguyen, C., Bhagwakar, J., Jovanoski, N. ELSEVIER SCIENCE INC. 2022: S253

View details for Web of Science ID 000858678100415